SSTR1 and prostate cancer: This cell type-specific response was further confirmed as 5-AZA-dC treatment was associated with SSTR1 hypomethylation in androgen receptor-positive prostate cancer cell line, whereas this was not observed in an androgen-receptor negative prostate cancer cell line [82].